Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2022 | Centralized vs decentralized manufacturing of CAR-T therapies

Ulrike Koehl • 7 Feb 2022
CAR-T Meeting 2022
General CAR-T

Ulrike Koehl, MD, PhD, University of Leipzig, Leipzig, Germany, outlines the purpose of centralized and decentralized manufacturing of chimeric antigen receptor T-cell (CAR-T) therapies. Whilst decentralized manufacturing is required in early phase clinical trials to transfer new innovations to patients rapidly, centralized manufacturing is needed to address a larger number of patients in late phase clinical trials. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.

Disclosures

Cooperation: Novartis, Miltenyi Biotec
Consulting: AstraZeneca, Affimed, Glycostem, GammaDelta, Zelluna

More from Ulrike Koehl

0:46
Scaling up CAR-T manufacturing with automation and digitalization
Ulrike Koehl • 7 Feb 2022
0:56
Minimizing the costs of CAR-T manufacturing
Ulrike Koehl • 7 Feb 2022
0:44
NK cells vs T-cells
Ulrike Koehl • 7 Feb 2022
1:14
Optimizing NK cell manufacturing
Ulrike Koehl • 7 Feb 2022

Related Videos

3:12
Addressing cardiotoxicity following CAR-T therapy and improving clinical practice
Arjun Ghosh • 25 Apr 2024
4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals